Literature DB >> 10067843

1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast.

B Ecarot1, M Desbarats.   

Abstract

Mutations in the PHEX/Phex gene, which encodes for a protein with homology to neutral endopeptidases, are responsible for human and murine X-linked hypophosphatemia. The present study examined Phex messenger RNA (mRNA) and protein expression in cultured osteoblasts and its regulation by 1,25-(OH)2D3. Phex mRNA levels were quantitated on Northern blots by densitometric analysis relatively to GAPDH mRNA levels. Immunoreactive Phex protein levels were evaluated by immunoprecipitation using a polyclonal rabbit antiserum raised against a mouse Phex carboxy-terminal peptide. Beta-glycerophosphate-induced matrix mineralization in primary osteoblast cultures was associated with significant increases in Phex mRNA and protein. Phex mRNA and protein levels were low or undetectable in proliferating preosteoblastic MC3T3-E1 cells and dramatically increased concomitantly with initiation of matrix mineralization. The pattern of Phex expression, however, was similar in nonmineralizing cultures grown in the absence of beta-glycerophosphate, indicating that the induction of Phex expression in MC3T3-E1 cells was related to cell differentiation rather than matrix mineralization. 1,25-(OH)2D3 inhibited mineral deposition and down-regulated Phex mRNA and protein expression in a time- and dose-dependent manner. These results indicate that Phex is a marker of the fully differentiated osteoblast and that its expression is stimulated during beta-glycerophosphate-induced mineralization in primary osteoblast cultures and down-regulated by 1,25-(OH)2D3, an inhibitor of matrix mineralization. These findings add support for Phex having an important role in bone mineralization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067843     DOI: 10.1210/endo.140.3.6593

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  The molecular background to hypophosphataemic rickets.

Authors:  P S Rowe
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 2.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

3.  Vitamin D represses dentin matrix protein 1 in cementoblasts and osteocytes.

Authors:  F H Nociti; B L Foster; A B Tran; D Dunn; R B Presland; L Wang; N Bhattacharyya; M T Collins; M J Somerman
Journal:  J Dent Res       Date:  2013-12-11       Impact factor: 6.116

4.  MRNA expression of Phex in mice and rats: the effect of low phosphate diet.

Authors:  M H Meyer; R A Meyer
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

Review 5.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

6.  Effects of phosphates on the expression of tissue-nonspecific alkaline phosphatase gene and phosphate-regulating genes in short-term cultures of human osteosarcoma cell lines.

Authors:  Hideo Orimo; Takashi Shimada
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

7.  Transgenic overexpression of bone morphogenetic protein 11 propeptide in skeleton enhances bone formation.

Authors:  Zicong Li; Fang Zeng; Alva D Mitchell; Yong Soo Kim; Zhenfang Wu; Jinzeng Yang
Journal:  Biochem Biophys Res Commun       Date:  2011-11-10       Impact factor: 3.575

Review 8.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

9.  The role of tissue-nonspecific alkaline phosphatase in the phosphate-induced activation of alkaline phosphatase and mineralization in SaOS-2 human osteoblast-like cells.

Authors:  Hideo Orimo; Takashi Shimada
Journal:  Mol Cell Biochem       Date:  2008-05-26       Impact factor: 3.396

10.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.